EGFR-targeted therapies in lung cancer: predictors of response and toxicity

被引：57

作者：

Heist, Rebecca Suk ^{[1
]}

Christiani, David ^{[1
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA

来源：

PHARMACOGENOMICS | 2009年 / 10卷 / 01期

关键词：

cancer genetics; EGFR; lung cancer; predictive markers; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; PREVIOUSLY TREATED PATIENTS; CETUXIMAB PLUS IRINOTECAN; KRAS MUTATIONS; GEFITINIB SENSITIVITY; MOLECULAR PREDICTORS; DINUCLEOTIDE REPEAT; MONOCLONAL-ANTIBODY;

D O I：

10.2217/14622416.10.1.59

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.

引用

页码：59 / 68

页数：10

共 79 条

[41] Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications [J].

Kosaka, T ;

Yatabe, Y ;

Endoh, H ;

Kuwano, H ;

Takahashi, T ;

Mitsudomi, T .

CANCER RESEARCH, 2004, 64 (24) :8919-8923

[42] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[43]

Lee D, 2008, J CLIN ONCOL, V26

[44]

Li J, 2005, CLIN CANC RES S, V11S, P120

[45] Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients [J].

Li, Jing ;

Cusatis, George ;

Brahmer, Julie ;

Sparreboom, Alex ;

Robey, Robert W. ;

Bates, Susan E. ;

Hidalgo, Manuel ;

Baker, Sharyn D. .

CANCER BIOLOGY & THERAPY, 2007, 6 (03) :432-438

[46] KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].

Lievre, Astrid ;

Bachet, Jean-Baptiste ;

Boige, Valerie ;

Cayre, Anne ;

Le Corre, Delphine ;

Buc, Emmanuel ;

Ychou, Marc ;

Bouche, Olivier ;

Landi, Bruno ;

Louvet, Christophe ;

Andre, Thierry ;

Bibeau, Frederic ;

Diebold, Marie-Daniele ;

Rougier, Philippe ;

Ducreux, Michel ;

Tomasic, Gorana ;

Emile, Jean-Francois ;

Penault-Llorca, Frederique ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379

[47] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib [J].

Liu, G. ;

Gurubhagavatula, S. ;

Zhou, W. ;

Wang, Z. ;

Yeap, B. Y. ;

Asomaning, K. ;

Su, L. ;

Heist, R. ;

Lynch, T. J. ;

Christiani, D. C. .

PHARMACOGENOMICS JOURNAL, 2008, 8 (02) :129-138

[48]

Liu WQ, 2005, CANCER RES, V65, P46

[49]

Liu WQ, 2003, CLIN CANCER RES, V9, P1009

[50] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

← 1 2 3 4 5 6 7 8 →